ST. LOUIS , July 19 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company that uses medical genomics to keep people healthier, will explain today how it can save healthcare costs by avoiding hospitalization for employees with high blood pressure, diabetes, and emphysema.

GenoMed is making its presentation over lunch today to 10 Midwest employers who belong to The ECCHIC Group. These firms employ about 500 people, and collectively spend about $3 million annually on health insurance. GenoMed will describe how to save 25% within the first 12 months, with ongoing savings and better patient outcomes over the years to come.

Said David Moskowitz MD, GenoMed's CEO, 'By avoiding hospitalization, GenoMed can make patients suitable for a high-deductible health plan, which can be up to 40% less expensive than conventional health insurance. Typically, annual health insurance premiums can be reduced from $6,000 to $4,500 , for a 25% savings.'

Dr. Moskowitz added, 'President Bush is vigorously promoting the use of health savings accounts (HSA's) and high-deductible health insurance for all employees, including those currently without health insurance. GenoMed is proud to team up with The ECCHIC Group to help make the President's vision a reality.'

About The ECCHIC Group

ECCHIC (Employers Committed to Control Health Insurance Costs) is a group of 200 companies with an average of 50 employees or less, located primarily in rural Missouri and Kansas. Employee turnover is usually low in these companies. Small employers are among the most proactive nationally in trying to rein in the sky-rocketing cost of healthcare. Few health insurance brokers nationally have been as successful as those at The ECCHIC Group in lowering healthcare costs for their clients while enhancing quality.

About GenoMed

GenoMed is a Next Generation DM(TM) company that can significantly lower healthcare costs for working adults and retirees by delaying, or even reversing, the progression of three of the most common diseases in the U.S.: high blood pressure, diabetes, and emphysema. GenoMed has published and applied for patent protection on its unique treatment protocols, and charges an $800 annual fee to the patient. This includes a licensing fee as well as the cost of GenoMed's Next Generation DM(TM) service.

Safe Harbor Statement

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases 'ought to,' 'should,' 'could,' 'may,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

SOURCE GenoMed